AstraZeneca PLC (NYSE: AZN) reported first-quarter 2026 financial results with total revenue of USD 15.288 billion, representing 8% year-over-year (YOY) growth. The performance was primarily driven by double-digit growth in Oncology (+16%) and Rare Disease (+15%) divisions, offsetting a slight decline in Biopharmaceuticals (-2%) and cardiovascular headwinds from China’s volume-based procurement implementation.
Financial Highlights – Q1 2026
Metric
Q1 2026
YOY Change
Total Revenue
USD 15.288 billion
+8%
Product Sales
USD 15.211 billion
+8%
Oncology Division
USD 6.797 billion
+16%
Biopharmaceuticals
USD 5.741 billion
-2%
Rare Disease
USD 2.420 billion
+15%
Geographic Performance
Region
Q1 2026 Sales
YOY Change
United States
USD 6.204 billion
+10%
Europe
USD 3.405 billion
+9%
Emerging Markets (ex-China)
USD 2.475 billion
+9%
China
USD 1.923 billion
+2%
Established Rest of World (ERoW)
USD 1.204 billion
+2%
Oncology Portfolio Breakdown
Product
Q1 2026 Sales
YOY Change
Key Dynamics
Tagrisso (osimertinib)
USD 1.833 billion
+5%
Strong demand across multiple indications maintains market leadership
Imfinzi (durvalumab)
USD 1.694 billion
+30%
Exceptional growth driven by expanding indications in lung cancer and other solid tumors
Enhertu (trastuzumab deruxtecan)
USD 1.422 billion
+34%
Co-developed with Daiichi Sankyo; rapid adoption across HER2-positive cancers
Calquence (acalabrutinib)
USD 0.923 billion
+17%
Maintains BTK inhibitor leadership in first-line chronic lymphocytic leukemia
Other Therapeutic Areas
Cardiovascular
Farxiga (dapagliflozin): USD 2.237 billion (-2% YOY), impacted by China’s volume-based procurement (VBP) implementation in Q1 2026 and Emerging Markets decline of 2%
Respiratory & Immunology
Tezspire (tezepelumab): USD 493 million (+34% YOY), co-developed with Amgen, showing strong growth in severe asthma indication
Rare Disease
Ultomiris (ravulizumab): USD 1.270 billion (+18% YOY), including sales of Voydeya (danicopan) approved as add-on therapy for PNH patients with extravascular hemolysis
Clinical Setback: Phase III ARTEMIS trial for Ultomiris in cardiac surgery-associated acute kidney injury (CSA-AKI) terminated due to inconsistent efficacy
Strategic Implications & Market Outlook
Oncology Dominance: Oncology division now represents 45% of total revenue, demonstrating successful portfolio transformation
China Strategy Adaptation: VBP impact on Farxiga highlights need for pricing strategy adjustments in key emerging markets
Geographic Diversification: Strong U.S. and European performance provides stability against emerging market pricing pressures
Pipeline Focus: Termination of ARTEMIS trial allows reallocation of resources to higher-potential development programs
Forward‑Looking Statements This brief contains forward-looking statements regarding financial performance, product growth trajectories, and clinical development outcomes. Actual results may differ due to risks including competitive pressures, pricing dynamics, regulatory developments, and clinical trial results. AstraZeneca’s next quarterly results are scheduled for release on July 27, 2026.-Fineline Info & Tech
By Fineline Cube 